BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 34022680)

  • 1. Mutant CDKN2A regulates P16/p14 expression by alternative splicing in renal cell carcinoma metastasis.
    Sun Q; Chen S; Hou Y; Wen X; Teng X; Zhang H; Lai C; Lai M
    Pathol Res Pract; 2021 Jul; 223():153453. PubMed ID: 34022680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systematic analysis of alternative splicing signature unveils prognostic predictor for kidney renal clear cell carcinoma.
    Song J; Liu YD; Su J; Yuan D; Sun F; Zhu J
    J Cell Physiol; 2019 Dec; 234(12):22753-22764. PubMed ID: 31140607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p14 expression differences in ovarian benign, borderline and malignant epithelial tumors.
    Cabral VD; Cerski MR; Sa Brito IT; Kliemann LM
    J Ovarian Res; 2016 Oct; 9(1):69. PubMed ID: 27770808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CDKNA2A mutation analysis, protein expression, and deletion mapping of chromosome 9p in conventional clear-cell renal carcinomas: evidence for a second tumor suppressor gene proximal to CDKN2A.
    Schraml P; Struckmann K; Bednar R; Fu W; Gasser T; Wilber K; Kononen J; Sauter G; Mihatsch MJ; Moch H
    Am J Pathol; 2001 Feb; 158(2):593-601. PubMed ID: 11159196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-cell analysis reveals metastatic cell heterogeneity in clear cell renal cell carcinoma.
    Liu K; Gao R; Wu H; Wang Z; Han G
    J Cell Mol Med; 2021 May; 25(9):4260-4274. PubMed ID: 33759378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic analysis of survival-associated alternative splicing signatures in clear cell renal cell carcinoma.
    Chen T; Zheng W; Chen J; Lin S; Zou Z; Li X; Tan Z
    J Cell Biochem; 2020 Oct; 121(10):4074-4084. PubMed ID: 31886566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CDKN2A germline splicing mutation affecting both p16(ink4) and p14(arf) RNA processing in a melanoma/neurofibroma kindred.
    Petronzelli F; Sollima D; Coppola G; Martini-Neri ME; Neri G; Genuardi M
    Genes Chromosomes Cancer; 2001 Aug; 31(4):398-401. PubMed ID: 11433531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2.
    Stott FJ; Bates S; James MC; McConnell BB; Starborg M; Brookes S; Palmero I; Ryan K; Hara E; Vousden KH; Peters G
    EMBO J; 1998 Sep; 17(17):5001-14. PubMed ID: 9724636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic status of cell cycle regulators in squamous cell carcinoma of the oesophagus: the CDKN2A (p16(INK4a) and p14(ARF) ) and p53 genes are major targets for inactivation.
    Smeds J; Berggren P; Ma X; Xu Z; Hemminki K; Kumar R
    Carcinogenesis; 2002 Apr; 23(4):645-55. PubMed ID: 11960918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microsatellite alteration and immunohistochemical expression profile of chromosome 9p21 in patients with sporadic renal cell carcinoma following surgical resection.
    El-Mokadem I; Lim A; Kidd T; Garret K; Pratt N; Batty D; Fleming S; Nabi G
    BMC Cancer; 2016 Jul; 16():546. PubMed ID: 27465101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis.
    Clifford SC; Prowse AH; Affara NA; Buys CH; Maher ER
    Genes Chromosomes Cancer; 1998 Jul; 22(3):200-9. PubMed ID: 9624531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive analyses of cuproptosis-related gene CDKN2A on prognosis and immunologic therapy in human tumors.
    Zhang D; Wang T; Zhou Y; Zhang X
    Medicine (Baltimore); 2023 Apr; 102(14):e33468. PubMed ID: 37026918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aberrations of the p14(ARF) and p16(INK4a) genes in renal cell carcinomas.
    Kawada Y; Nakamura M; Ishida E; Shimada K; Oosterwijk E; Uemura H; Hirao Y; Chul KS; Konishi N
    Jpn J Cancer Res; 2001 Dec; 92(12):1293-9. PubMed ID: 11749694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive analysis on the expression levels and prognostic values of LOX family genes in kidney renal clear cell carcinoma.
    Lin S; Zheng L; Lu Y; Xia Q; Zhou P; Liu Z
    Cancer Med; 2020 Nov; 9(22):8624-8638. PubMed ID: 32970930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression and significance of histone H3K27 demethylases in renal cell carcinoma.
    Shen Y; Guo X; Wang Y; Qiu W; Chang Y; Zhang A; Duan X
    BMC Cancer; 2012 Oct; 12():470. PubMed ID: 23057811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The molecular pathogenesis and prognosis of renal cell carcinoma].
    Serth J
    Urologe A; 2007 Sep; 46(9):1168-9. PubMed ID: 17668170
    [No Abstract]   [Full Text] [Related]  

  • 17. Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas.
    Boström J; Meyer-Puttlitz B; Wolter M; Blaschke B; Weber RG; Lichter P; Ichimura K; Collins VP; Reifenberger G
    Am J Pathol; 2001 Aug; 159(2):661-9. PubMed ID: 11485924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequent deletion and methylation in SH3GL2 and CDKN2A loci are associated with early- and late-onset breast carcinoma.
    Sinha S; Chunder N; Mukherjee N; Alam N; Roy A; Roychoudhury S; Kumar Panda C
    Ann Surg Oncol; 2008 Apr; 15(4):1070-80. PubMed ID: 18239974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomic instability, mutations and expression analysis of the tumour suppressor genes p14(ARF), p15(INK4b), p16(INK4a) and p53 in actinic keratosis.
    Kanellou P; Zaravinos A; Zioga M; Stratigos A; Baritaki S; Soufla G; Zoras O; Spandidos DA
    Cancer Lett; 2008 Jun; 264(1):145-61. PubMed ID: 18331779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic role of E2F1 and members of the CDKN2A network in gastrointestinal stromal tumors.
    Haller F; Gunawan B; von Heydebreck A; Schwager S; Schulten HJ; Wolf-Salgó J; Langer C; Ramadori G; Sültmann H; Füzesi L
    Clin Cancer Res; 2005 Sep; 11(18):6589-97. PubMed ID: 16166437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.